logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
RNAC
Cartesian Therapeutics, Inc.
7.05
2 x 5.98
2 x 10.59
bid
ask
+
0.23
3.45%
2 @ 04:00 PM
7.05 +0.00 (0.00%)
Ytd-2.15%
1y-30.15%
6.85
day range
7.17
5.84
52 week range
10.59
Open6.87Prev Close6.82Low6.85High7.17Mkt Cap213.45M
Vol114.55KAvg Vol133.50KEPS-5.78P/EN/AForward P/E-5.54
Beta0.65Short Ratio15.83Inst. Own27.85%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg8.46200-d Avg7.701yr Est38.17

RNAC News

benzinga.com
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC
benzinga.com
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
benzinga.com
Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Desca

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treat
benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
benzinga.com
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the a

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
benzinga.com
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthe

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
benzinga.com
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maint

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen

WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Des
benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
benzinga.com
Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40

Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the
benzinga.com
Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expec

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology c
benzinga.com
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC)
benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
benzinga.com
Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the
benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
benzinga.com
Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target

Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutr
benzinga.com
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
benzinga.com
CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the

Insights into Cartesian Therapeutics Q4 Earnings
benzinga.com
Insights into Cartesian Therapeutics Q4 Earnings
benzinga.com
Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42

Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
benzinga.com
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim
benzinga.com
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $30

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC)

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
benzinga.com
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
BTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44

BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises
benzinga.com
Cartesian Therapeutics Data From Phase 2 Study Of Descartes-08 Demonstrates 100% Lupus Low Disease A

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology c
benzinga.com
Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estima

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarke
benzinga.com
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Sessio

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed t
benzinga.com
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga.com
LivePerson And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shar